STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Zai Lab Ltd SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Zai Lab Ltd (ZLAB) filed a Form 144 reporting a proposed sale of 456 American Depositary Shares (ADS) with an aggregate market value of $15,616.6810/02/2025 through Fidelity Brokerage Services on NASDAQ. The ADS were acquired on 10/01/2025 via restricted stock vesting and were paid as compensation. The filer also disclosed two prior sales in the last three months: 4,096 ADS sold on 08/08/2025 for $139,304.96 and 1,438 ADS sold on 08/15/2025 for $50,931.59. Total shares outstanding reported are 421,725,450. The filing includes the standard representation that the seller is unaware of any undisclosed material adverse information.

Positive
  • Disclosure compliance: Form 144 filed and includes acquisition, sale dates, amounts, and broker information
  • Source of shares disclosed: 456 ADS were acquired via restricted stock vesting and paid as compensation
Negative
  • Insider selling activity: 5,534 ADS sold in the past three months for total gross proceeds of $190,236.55
  • Small transaction relative to shares outstanding: While disclosed, the proposed 456 ADS represent a very small fraction of the 421,725,450 outstanding shares

Insights

TL;DR: Insider plans to sell a small block of ADS after recent vesting; prior open-market sales were disclosed.

The filing shows the sale arises from newly vested restricted ADS reported as compensation on 10/01/2025, with a proposed sale of 456 ADS on 10/02/2025 through Fidelity. The filer also disclosed two open-market sales in August totaling 5,534 ADS and roughly $190,236 in gross proceeds. These disclosures meet Rule 144 notice requirements and provide transparent timing and proceeds for investor review.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What is being proposed for sale in the ZLAB Form 144?

The filer proposes to sell 456 American Depositary Shares on 10/02/2025 through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $15,616.68.

How were the 456 ADS acquired according to the filing?

The 456 ADS were acquired on 10/01/2025 through restricted stock vesting and were received as compensation.

What prior insider sales does the Form 144 disclose for ZLAB?

Two prior sales are disclosed: 4,096 ADS sold on 08/08/2025 for $139,304.96 and 1,438 ADS sold on 08/15/2025 for $50,931.59.

How many Zai Lab shares are outstanding per this filing?

The filing reports 421,725,450 shares outstanding.

Which broker will handle the proposed sale?

The filing lists Fidelity Brokerage Services LLC at the Smithfield, RI address as the broker.
Zai Lab Limited

NASDAQ:ZLAB

ZLAB Rankings

ZLAB Latest News

ZLAB Latest SEC Filings

ZLAB Stock Data

2.27B
107.02M
1.74%
42.53%
4.26%
Biotechnology
Pharmaceutical Preparations
Link
China
SHANGHAI